Amgen's Enemies

Dolan, Kerry A.
October 2006
Forbes Asia;10/30/2006, Vol. 2 Issue 18, p36
The article focuses on issues facing Amgen Inc. despite its success in 2006. One issue is that the company's patents are expiring. The second issue is the possibility that the sales tactics of the company could come back to haunt it because it uses leverage from a drug to pressure doctors into prescribing the Amgen product in a competitive market. The third problem is the existence of a dispute about whether certain Amgen patients are getting more of one costly drug than they really need.


Related Articles

  • Enbrel patent surfaces. Harrison, Charlotte // Nature Biotechnology;Feb2012, Vol. 30 Issue 2, p123 

    The article reports on the 17 years of patent protection received by Amgen for its autoimmune drug Enbrel. The patent entails that the drug can be marketed for 30 years before it faces competition from biosimilars, such as one that is planned to be developed by Merck. The drug, which has been...

  • Cinacalcet approved for treating hyperparathyroidism, hypercalcemia. Lamb, Ed // Pharmacy Today;May2004, Vol. 10 Issue 5, p10 

    Reports on the marketing approval granted by the U.S. Food and Drug Administration for cinacalcet, an agent for the treatment of hyperparathyroidism and hypercalcemia developed by Amgen Inc. Explanations concerning cinacalcet; Information on hyperparathyroidism; Account of treatment options for...

  • Amgen Looks to Future.  // Chain Drug Review;5/23/2011, Vol. 33 Issue 9, p75 

    The article reports on the business strategy and capital allocation plans outlined by Amgen Inc. at its meeting in the U.S.

  • Local 'Seoul': Epirus Approach to Biosimilars Is Portable, Simple. Osborne, Randy // BioWorld Today;9/3/2013, Vol. 24 Issue 168, p1 

    The article discusses the in-market, for-market approach employed by biotechnology company Epirus Biopharmaceuticals Inc. in the production and marketing of its biosimilars as a way to compete with pharmaceutical companies such as Amgen Inc., Celltrion Inc., and Pfizer Inc. It states that the...

  • Regeneron's Eylea Tops Rivals. Investor's Business Daily // Investors Business Daily;10/20/2014, pA01 

    8 Clinical trial results show that

  • XGEVA.  // MPR - Urologists' Edition;Spring/Summer2011, Vol. 8 Issue 1, pA8 

    The article offers information on XGEVA drug from Amgen Inc.

  • FDA probes tampering of Amgen products. Dickinson, James G. // Medical Marketing & Media;Apr2001, Vol. 36 Issue 4, p34 

    Reports on the investigation of the U.S. Food and Drug Administration on the tampering of Amgen Inc.'s products. Citation of the product tampering; Possibility of the safety risk for the patients; Total number of tampering incidents reported.

  • WEEK IN WASHINGTON.  // BioWorld Insight;6/18/2012, Vol. 20 Issue 25, p6 

    The article offers news briefs from Washington on topics including the U.S. Supremen Court's hearing of the fraud of Amgen Inc., cancellation of an accelerated approval for Pfizer Inc.'s Celebrex, a drug, and actions of several U.S. House committes concerning penalties for counterfeiting of drugs.

  • Amgen recalls anemia drugs due to glass flakes.  // Tennessee Tribune;9/30/2010, Vol. 21 Issue 39, p5B 

    The article reports on the recall of anemia treatment drugs Epogen and Procrit by Amgen Inc. due to its tendency to cause blood clots, veins swelling and immune system reactions in the U.S.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics